Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2016-12-12 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about Phase IIa clinical trial results. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F (annual reports). The document is short (1936 characters) and primarily serves as a regulatory announcement of a press release rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2016-12-12 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at the Jefferies Microbiome Summit. The document is short (1877 characters) and primarily serves as an announcement of an event rather than containing detailed financial data or a full report. Form 6-K filings are typically used for current reports by foreign private issuers and often include press releases or other material information. Since this document is an announcement of a presentation and does not contain financial statements or detailed analysis, it does not qualify as an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a Regulatory Filing in the sense of certifications or compliance documents, but rather a general regulatory announcement. Given the content and length, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-12-05 English
SC 13G
Major Shareholding Notification
2016-11-25 English
FORM 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a poster presentation at a cancer therapeutics symposium. The document is short (1961 characters) and primarily serves as a regulatory filing to report material information between annual reports. It does not contain financial statements or detailed financial analysis, nor is it an announcement of voting results, management changes, or capital updates. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they report miscellaneous material information for foreign issuers. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-11-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at the German Equity Forum 2016. The document is short (1875 characters) and primarily serves as a report of a press release rather than containing detailed financial data or comprehensive reporting. Form 6-K filings are typically used for current reports by foreign private issuers and often include announcements or presentations rather than full financial reports. Given the content and length, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-11-16 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., reporting condensed interim unaudited financial information for the nine and three months ended September 30, 2016. Form 6-K is used by foreign private issuers to report interim financial information and other material events between annual reports. The document includes interim financial data but is not a full annual report (10-K or 20-F). Given the presence of condensed interim unaudited financial information and the nature of Form 6-K filings, this corresponds to an Interim / Quarterly Report (IR). The document length is 2030 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, the appropriate classification is IR with high confidence.
2016-11-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.